https://doi.org/10.55788/e846deae
Robust evidence regarding the effectiveness of mini-slings compared with the effectiveness of mid-urethral slings is lacking, said Prof. Mohamed Abdel-fattah (University of Aberdeen, UK). Therefore, his group conducted the pragmatic multicentre, non-inferiority, randomised-controlled SIMS trial, including 600 adult women with SUI who failed or declined conservative treatment, and received an adjustable anchored mini-sling or a tension-free standard mid-urethral sling. The patient global impression of improvement (PGI-I) questionnaire at 15 months was the primary measure of treatment success.
According to the PGI-I results at 15 months, the success rate of mini-slings (79.1%) was non-inferior to that of standard mid-urethral slings (75.6%). The 3-year results displayed a similar result, with success rates of 72.0% and 66.8% in the experimental arm and control arm, respectively. The post-operative hospital stay was shorter in the experimental arm than in the control arm (7.2 hr vs 9.7 hr). However, no substantial difference was reported in the percentage of patients that had returned to normal activities within 28 days after surgery (75.2% vs 70.8%). Prof. Abdel-fattah added that the rates of ‘any degree’ groin or thigh pain were similar for both arms, with 14% of the patients experiencing these complaints at 36 months, but that the 36-month dyspareunia rate was higher in the experimental arm than in the control arm (11.7% vs 4.8%).
- Abdel-fattah M, et al. Single-Incision Mini-Slings for Stress Urinary Incontinence in Women. Game-changing session 4, EAU 2022, 01–04 July.
- Abdel-fattah M, et al. N Engl J Med 2022;386:1230.-1243
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Non-inferiority of methenamine hippurate to antibiotics in recurrent UTIs Next Article
Novel therapeutic targets for benign prostatic hyperplasia »
« Non-inferiority of methenamine hippurate to antibiotics in recurrent UTIs Next Article
Novel therapeutic targets for benign prostatic hyperplasia »
Table of Contents: EAU 2022
Featured articles
Darolutamide performs well across subgroups in mHSPC
Genitourinary Cancer
Does systematic biopsy add value to the detection rate of prostate cancer?
PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer
Prostate cancer treatments reduce quality of life
PROpel: Good results for abiraterone plus olaparib in mCRPC
Neoadjuvant hormonal therapy promising in high-risk prostate cancer
Darolutamide performs well across subgroups in mHSPC
Shorter hospital stay with robotic surgery versus open surgery in bladder cancer
Improved risk stratification for high-risk NMIBC
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma
New prognostication in N3 penile cancer
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC
Fewer complications with robotic surgery in renal cancer
Functional Urology
Novel therapeutic targets for benign prostatic hyperplasia
Mini-slings non-inferior to standard mid-urethral slings in SUI
Non-inferiority of methenamine hippurate to antibiotics in recurrent UTIs
Related Articles
December 25, 2020
Prostate biopsy needn’t substantially delay laser enucleation
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com